PPSMA-101 is under clinical development by Poseida Therapeutics and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PPSMA-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
P-PSMA-101 is under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and salivary gland cancer. The therapy constitutes chimeric antigen receptor (CAR) modified autologous T cells targeting prostate-specific membrane antigen (PSMA). P-PSMA-101 employs a PSMA-specific Centyrin binding domain. It is developed based on piggyBac (DNA modification system) footprint-free gene editing system and Teneobio’s UniDab technology and uses non-viral vector. It is administered through intravenous route.
Poseida Therapeutics overview
Poseida Therapeutics is a biopharmaceutical company. It harnesses its proprietary gene engineering platform, to develop next generation cell and gene therapeutics to treat solid tumors and hematological malignancies. The company is investigating its lead product candidate P-BCMA-101, an autologous CAR-T therapy against refractory multiple myeloma. It is also evaluating P-PSMA-101 and P-PSMA-ALL01, allogeneic chimeric antigen receptors for the treatment of prostate cancer; and Dual car (CD19/CD20) targeting solid tumor. Poseida Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of PPSMA-101’s drug-specific PTSR and LoA scores, buy the report here.